- Home
- NBIX vs ALLY Comparison
NBIX vs ALLY Comparison
Compare NBIX & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBIX | ALLY |
|---|---|---|
| Founded | 1992 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.1B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NBIX | ALLY |
|---|---|---|
| Price | $137.43 | $42.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 16 |
| Target Price | ★ $176.24 | $50.00 |
| AVG Volume (30 Days) | 1.1M | ★ 3.8M |
| Earning Date | 02-11-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 2.84% |
| EPS Growth | 12.44 | ★ 31.90 |
| EPS | ★ 4.19 | 2.37 |
| Revenue | $2,682,700,000.00 | ★ $7,374,000,000.00 |
| Revenue This Year | $23.55 | $24.88 |
| Revenue Next Year | $19.18 | $5.86 |
| P/E Ratio | $32.13 | ★ $17.85 |
| Revenue Growth | ★ 19.61 | 9.23 |
| 52 Week Low | $84.23 | $29.52 |
| 52 Week High | $160.18 | $47.27 |
Technical Indicators
Market Signals| Indicator | NBIX | ALLY |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 45.80 |
| Support Level | $132.75 | $41.93 |
| Resistance Level | $138.74 | $43.25 |
| Average True Range (ATR) | 3.36 | 1.19 |
| MACD | 0.55 | -0.25 |
| Stochastic Oscillator | 86.35 | 47.36 |
Price Performance
Historical ComparisonAbout NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.